Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making.
Search
Recent Posts
See AllBy: Harrison Weber With venture capital pouring record amounts of money into Los Angeles tech, small startups are seeing a boon. Seed deals hit new highs in the first half of this year, topping $330 m
Key takeaways • Real-world evidence (RWE) has the potential to be useful across the entire healthcare ecosystem, including for clinical trials, care provision, determining treatment outcomes, and post
Despite devastating the global economy and harming the health of millions, the COVID-19 pandemic prompted a boost in health care innovation. That’s according to David Whelan, CEO at BioscienceLA, to w